David B Badesch

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi request reprint Clinical trials in pulmonary hypertension
    D B Badesch
    University of Colorado Health Sciences Center, Denver 80262, USA
    Annu Rev Med 48:399-408. 1997
  2. ncbi request reprint Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
    D B Badesch
    Division of Pulmonology, University of Colorado, Denver 80262, USA
    Ann Intern Med 132:425-34. 2000
  3. ncbi request reprint Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 126:35S-62S. 2004
  4. ncbi request reprint Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Box C 272, 4200 E Ninth Ave, Denver, CO 80262, USA
    Chest 131:1917-28. 2007
  5. ncbi request reprint Prostanoid therapy for pulmonary arterial hypertension
    David B Badesch
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Am Coll Cardiol 43:56S-61S. 2004
  6. doi request reprint Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
    David B Badesch
    Department of Medicine, University of Colorado Denver, Denver, Colorado, USA
    J Rheumatol 36:2244-9. 2009
  7. ncbi request reprint Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Rheumatol 34:2417-22. 2007
  8. pmc Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease
    Kari E Roberts
    Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Am J Respir Crit Care Med 179:835-42. 2009
  9. doi request reprint Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study
    Lewis J Rubin
    Department of Medicine, University of California at San Diego, UCSD Medical Center Thornton, 9300 Campus Point Dr MC 7372, La Jolla, CA 92037, USA
    Chest 140:1274-83. 2011
  10. doi request reprint Diagnosis and assessment of pulmonary arterial hypertension
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80045, USA
    J Am Coll Cardiol 54:S55-66. 2009

Research Grants

Detail Information

Publications35

  1. ncbi request reprint Clinical trials in pulmonary hypertension
    D B Badesch
    University of Colorado Health Sciences Center, Denver 80262, USA
    Annu Rev Med 48:399-408. 1997
    ..Treatments showing promise at the level of small pilot studies within a single center should be studied more rigorously...
  2. ncbi request reprint Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
    D B Badesch
    Division of Pulmonology, University of Colorado, Denver 80262, USA
    Ann Intern Med 132:425-34. 2000
    ..Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum of disease for which no treatment has been proven effective in a randomized trial...
  3. ncbi request reprint Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Chest 126:35S-62S. 2004
    ..Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center...
  4. ncbi request reprint Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines
    David B Badesch
    University of Colorado Health Sciences Center, Box C 272, 4200 E Ninth Ave, Denver, CO 80262, USA
    Chest 131:1917-28. 2007
    ..Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended...
  5. ncbi request reprint Prostanoid therapy for pulmonary arterial hypertension
    David B Badesch
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Am Coll Cardiol 43:56S-61S. 2004
    ..In conclusion, though treatment with prostanoids is complicated by their generally short half-lives and complicated drug delivery systems, they continue to play an important role in the treatment of PAH...
  6. doi request reprint Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol
    David B Badesch
    Department of Medicine, University of Colorado Denver, Denver, Colorado, USA
    J Rheumatol 36:2244-9. 2009
    ..v.) infusion in an uncontrolled open-label 3-year extension study following an initial randomized, controlled 12-week study...
  7. ncbi request reprint Sildenafil for pulmonary arterial hypertension associated with connective tissue disease
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Rheumatol 34:2417-22. 2007
    ..The phosphodiesterase-5 inhibitor sildenafil citrate enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH. We examined the efficacy and safety of oral sildenafil in patients with PAH-CTD...
  8. pmc Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease
    Kari E Roberts
    Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA
    Am J Respir Crit Care Med 179:835-42. 2009
    ..Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant candidates. The pathogenesis of this complication of portal hypertension is poorly understood...
  9. doi request reprint Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study
    Lewis J Rubin
    Department of Medicine, University of California at San Diego, UCSD Medical Center Thornton, 9300 Campus Point Dr MC 7372, La Jolla, CA 92037, USA
    Chest 140:1274-83. 2011
    ..The long-term safety and tolerability of sildenafil treatment of pulmonary arterial hypertension (PAH) were assessed...
  10. doi request reprint Diagnosis and assessment of pulmonary arterial hypertension
    David B Badesch
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado 80045, USA
    J Am Coll Cardiol 54:S55-66. 2009
    ....
  11. ncbi request reprint Importance of right ventricular end-systolic regional wall stress in idiopathic pulmonary arterial hypertension: a new method for estimation of right ventricular wall stress
    Robert A Quaife
    Cardiac Imaging, Division of Cardiology, University of Colorado Health Sciences Center, B 120, 4200 East Ninth Avenue, Denver, Colorado 80262, USA
    Eur J Med Res 11:214-20. 2006
    ..0001). Right ventricular RWS is significantly elevated in IPAH and may provide a useful quantitative monitoring tool in patients with IPAH to assess the benefit of different therapeutic interventions and provide prognostic information...
  12. ncbi request reprint Pulmonary hypertension associated with connective tissue disease
    Karen A Fagan
    Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver, CO, USA
    Prog Cardiovasc Dis 45:225-34. 2002
    ..This report reviews the occurrence of this complication, potential etiologies, clinical presentation, and treatment options...
  13. doi request reprint Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry
    David B Badesch
    Divisions of Pulmonary Sciences and Critical Care Medicine, and Cardiology, University of Colorado Denver, Denver, CO, USA
    Chest 137:376-87. 2010
    ....
  14. doi request reprint ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension
    David B Badesch
    University of Colorado, 12401 E 17th Avenue, Aurora, CO 80045, USA
    Cardiovasc Ther 30:93-9. 2012
    ..Patients received 5 mg ambrisentan once daily for 24 weeks. The primary endpoint was change from baseline in 6-minute walk distance (6MWD) at week 24...
  15. ncbi request reprint Metastatic cancer while receiving continuous prostacyclin therapy
    Karen A Fagan
    Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, Denver, CO, USA
    Chest 128:619S-620S. 2005
  16. pmc Serotonin transporter polymorphisms in patients with portopulmonary hypertension
    Kari E Roberts
    Department of Medicine, Tufts Medical Center, Boston, MA, USA
    Chest 135:1470-5. 2009
    ..We hypothesized that the long allele or other polymorphisms in SERT would be associated with an increased risk of portopulmonary hypertension (PPHTN) in patients with advanced liver disease...
  17. doi request reprint Depressive symptoms in pulmonary arterial hypertension: prevalence and association with functional status
    Deborah H McCollister
    Pulmonary Hypertension Center, University of Colorado Denver, 12401 E 17th Ave, Box L957, Aurora, CO 80045, USA
    Psychosomatics 51:339-339.e8. 2010
    ..The prevalence of depressive symptoms, and their impact on patients with pulmonary arterial hypertension (PAH) is understudied...
  18. ncbi request reprint Autoimmunity and pulmonary hypertension: a perspective
    M R Nicolls
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Eur Respir J 26:1110-8. 2005
    ....
  19. ncbi request reprint Primary pulmonary hypertension, Castleman's disease and human herpesvirus-8
    T M Bull
    Dept of Medicine, Division of Pulmonary and Critical Care Medicine, Pulmonary Hypertension Center, Denver, CO 80262, USA
    Eur Respir J 22:403-7. 2003
    ..Evidence of human herpesvirus-8 infection was found in the lung tissue and, specifically, in the plexiform lesions from one of the patients...
  20. ncbi request reprint Pulmonary vascular manifestations of mixed connective tissue disease
    Todd M Bull
    Division of Pulmonary Sciences and Critical Care Medicine, Pulmonary Hypertension Center, University of Colorado School of Medicine, 4200 East Ninth Avenue, Box C 272, Denver, CO 80262, USA
    Rheum Dis Clin North Am 31:451-64, vi. 2005
    ..This article focuses on the pulmonary vasculature manifestations of MCTD. We briefly discuss associations between MCTD and interstitial lung disease, pleural disease, and alveolar hemorrhage...
  21. doi request reprint Surrogate and combined end points in pulmonary arterial hypertension
    Corey E Ventetuolo
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Proc Am Thorac Soc 5:617-22. 2008
    ..In addition, investigators have advocated the use of combined clinical end points in future clinical trials. The dependence of clinical trials and clinical management on such end points warrants a review of their use...
  22. ncbi request reprint Potassium and phosphorus repletion in hospitalized patients: implications for clinical practice and the potential use of healthcare information technology to improve prescribing and patient safety
    Brian A Hemstreet
    Department of Clinical Pharmacy, University of Colorado at Denver and Health Sciences Center School of Pharmacy, Denver, CO 80262, USA
    Curr Med Res Opin 22:2449-55. 2006
    ..Evaluate potassium and phosphorus repletion in hospitalized patients. Assess the potential role for use of various methods, including healthcare information technology, to improve prescribing and patient safety...
  23. ncbi request reprint Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics
    William T Abraham
    Department of Medicine, University of Colorado, School of Medicine, Denver, USA
    J Renin Angiotensin Aldosterone Syst 4:27-30. 2003
    ....
  24. ncbi request reprint Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension
    Vallerie V McLaughlin
    Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    J Cardiovasc Pharmacol 41:293-9. 2003
    ..Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term. Treprostinil can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system...
  25. ncbi request reprint Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study
    Olivier Sitbon
    Service de Pneumologie RĂ©animation Respiratoire, Hopital Antoine Beclere, 157, Avenue de la Porte Trivaux, F 92141 Clamart Cedex, France
    Chest 124:247-54. 2003
    ..We report on the long-term safety and efficacy of bosentan treatment in patients with pulmonary arterial hypertension (PAH)...
  26. ncbi request reprint Bosentan therapy for pulmonary arterial hypertension
    Lewis J Rubin
    Division of Pulmonary and Critical Care Medicine, University of California at San Diego, La Jolla 92037 1330, USA
    N Engl J Med 346:896-903. 2002
    ..The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses...
  27. ncbi request reprint Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    ..Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension...
  28. ncbi request reprint Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
    Vallerie V McLaughlin
    The University of Michigan Health System, Ann Arbor, Michigan, USA
    Am J Respir Crit Care Med 174:1257-63. 2006
    ..Small, open-label studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH)...
  29. pmc Clinical risk factors for portopulmonary hypertension
    Steven M Kawut
    Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH 8E, Room 101, New York, NY 10032, USA
    Hepatology 48:196-203. 2008
    ..24, 95% confidence interval 0.09-0.65, P = 0.005) of portopulmonary hypertension. The severity of liver disease was not related to the risk of portopulmonary hypertension...
  30. doi request reprint Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2
    Nazzareno Galie
    Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Circulation 117:3010-9. 2008
    ..Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension...
  31. doi request reprint Formulary management of recombinant factor VIIa at an academic medical center
    Phillip S Owen
    Department of Pharmacy Practice Clinical Assistant Professor, College of Pharmacy and Health Sciences Center, Mercer University, Atlanta, GA, USA
    Ann Pharmacother 42:771-6. 2008
    ..Concerns of potentially inappropriate use, safety, and cost of rVIIa led to efforts to standardize use of this agent...
  32. ncbi request reprint Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension
    David Langleben
    Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Am Heart J 143:E4. 2002
    ..Circulating mediators, including thromboxane A2, the vasoconstrictor, platelet aggregant, and smooth muscle mitogen, may contribute to the progression of vascular narrowing in primary pulmonary hypertension (PPH)...
  33. ncbi request reprint Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop
    John H Newman
    Departments of Medicine, Nashville VA Medical Center GRECC, and Vanderbilt University, Nashville, Tenn, USA
    Circulation 109:2947-52. 2004
  34. ncbi request reprint Evaluation and management of the patient with pulmonary arterial hypertension
    Lewis J Rubin
    University of California, San Diego, Medical Center, La Jolla, California 92037 7381, USA
    Ann Intern Med 143:282-92. 2005
    ..In this review, the authors present approaches to the diagnosis and management of pulmonary arterial hypertension, using a hypothetical case to highlight the key management points...
  35. doi request reprint Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival
    Raymond L Benza
    University of Alabama at Birmingham, 1900 University Blvd, Tinsley Harrison Towers, Room 328A, Birmingham, AL 35294, USA
    Chest 134:775-82. 2008
    ..Long-term efficacy evaluations are needed to guide therapeutic management. The purpose of this study is to present 1-year observational data with two endothelin antagonists, sitaxsentan and bosentan, in a prospective, open-label study...

Research Grants1

  1. RELATIVE ARGININE DEFICIENCY IN PULMONARY HYPERTENSION
    David Badesch; Fiscal Year: 2004
    ..abstract_text> ..